Serum Pepsinogen After H. Pylori Eradication

Status Completed

Clinical Trial Summary

Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis. Current guidelines recommend the H. pylori "test-and-treat" strategy for the purpose of primary and secondary gastric cancer prevention. Considering the "point of no return" theory, however, H. pylori eradication cannot reduce the risk of gastric cancer in subjects with gastric atrophy and intestinal metaplasia. The intragastric hypoacidic environment is associated with the risk of intestinal-type gastric cancer development. Recently, the secretory ability of the stomach can be measured using the serum pepsinogen (PG) assay.

Clinical Trial Description

This study aimed to evaluate the change of serum PGs after H. pylori eradication success and identify the optimal timing of eradication. ;

Study Design

Related Conditions & MeSH terms

Helicobacter Pylori Eradication

Clinical Trial Details

NCT number	NCT03924375
Study type	Observational
Source	Soonchunhyang University Hospital
Contact
Status	Completed
Phase
Start date	March 15, 2019
Completion date	May 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02873065` - Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori	Phase 4
Recruiting	`NCT06349486` - Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication	N/A
Recruiting	`NCT04034641` - Effect of Probiotics on Helicobacter Pylori Eradication	Phase 4
Completed	`NCT04850209` - The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori	N/A
Not yet recruiting	`NCT04558502` - Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication	Phase 4
Completed	`NCT06101420` - Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication	Phase 3
Recruiting	`NCT06088316` - Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT	Phase 4
Recruiting	`NCT05850117` - Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p	N/A
Recruiting	`NCT05191888` - 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy	Phase 4
Recruiting	`NCT05870397` - Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective Randomized Trial	N/A